Coronary artery bypass graft surgery in patients on ticagrelor therapy is not associated with adverse perioperative outcomes.
Sammer DiabMattan AraziLeonid SternikEhud RaananiErez KachelLiza Grosman-RimonAmjad ShalabiOffer AmirShemy CarassoPublished in: Journal of cardiothoracic surgery (2021)
Continuing ticagrelor until coronary artery bypass surgery was not associated with increased bleeding complications, suggesting that continued management with ticagrelor until surgery may be safe.
Keyphrases
- coronary artery bypass
- percutaneous coronary intervention
- st segment elevation myocardial infarction
- acute coronary syndrome
- st elevation myocardial infarction
- antiplatelet therapy
- coronary artery disease
- atrial fibrillation
- end stage renal disease
- newly diagnosed
- ejection fraction
- emergency department
- minimally invasive
- patients undergoing
- prognostic factors
- acute kidney injury
- stem cells
- mesenchymal stem cells
- insulin resistance